A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab
Simple summaryCombinations of monoclonal antibodies that activate the immune system have been highly effective for treatment of melanoma that has spread (metastasized). Unfortunately, this type of immunotherapy treatment can trigger serious side effect…